Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q4 2017 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$618.00K$618.00Kderivedno prior Q4 2016 on file Net Income-$2.70M-$2.70Mderivedno prior Q4 2016 on file EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$2,853,000N/M Operating Cash Flowderived-$2,048,000N/M Free Cash Flowderived-$2,050,000N/M Margins · derivedOperating margin-461.7%
Net margin-436.2%
ended Aug 31, 2017 · filed Nov 29, 2017 · 90 d after period end